Premium
IC‐P‐002: PET imaging of Alzheimer's disease (AD) transgenic mice with F‐18 labeled 8‐hydroxy quinoline
Author(s) -
Kulkarni Padmakar V.,
Vasdev Neil,
Arora Veera,
Hao Guiang,
Long Michael,
Slavine Nikolai,
Qu Bao-Xi,
Sun Xiankai,
Bennett Michael,
Antich Peter P.,
Bonte Frederick J.
Publication year - 2010
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2010.05.017
Subject(s) - chemistry , washout , clioquinol , pet imaging , nuclear medicine , genetically modified mouse , amyloid β , saline , positron emission tomography , pathology , transgene , medicine , biochemistry , endocrinology , disease , gene
and no distal cues, or (2) hippocampal-based spatial MWM with hidden platform and distal visual cues. Performance was assessed using escape latencies and probe trial parameters. Ten days post-training, mice were transcardially perfused. Brains within intact skulls were post-fixed and imaged using highresolution (32 micron isotropic) T2-weighted MRI at 7T. Deformation-based morphometry (DBM) was used to identify focal volume changes correlated with cognitive task performance using a general linear model (Lerch et al, 2008). Results: All mice undergoing the non-spatial MWM performed equally well. Focal volume increase associated with non-spatial MWM was observed in the striatum. On spatial MWM, APP mice displayed significantly prolonged escape latencies to reach the hidden platform compared to WT. Pioglitazone-treated APP mice exhibited a trend for reduced latencies during training, and a slightly higher number of platform-crossings than untreated APP mice during probe trial. Focal volume increase associated with spatial MWM performance was observed in the hippocampus in WT mice and treated APP mice, but not in untreated APP mice. Conclusions: We have demonstrated using high resolution MRI and DBM that spatial learning-induced hippocampal brain plasticity is absent in young APP mice. Pioglitazone-treatment in young APP mice had beneficial effects on focal hippocampal volume growth associated with spatial MWM performance, and completely rescued cerebrovascular function, suggesting that early and continued pioglitazone treatment may slow AD progression.